Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer

Current Opinion in Urology

Volumn 19, Issue 3, 2009, Pages 227-231

  Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Early detection; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN SPECIFICITY; CANCER RISK; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; NOMOGRAM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; AGED; BIOPSY; BLOOD; MALE; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NOMOGRAMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 67649695277     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328329a2d0     Document Type: Review

References (18)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156-1161.
2. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452-1455.
3. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:2698; author reply 2698-2699.
4. Heidenreich A, Aus G, Bolla M, et al., European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008; 53:68-80.
5. Schröder FH, Ballentine Carter H, Wolters T, et al. Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol 2008; 53:468-477. Specificity needs to be improved in the PSA range of 1.0-2.9 ng/ml, in the meantime, applying PSA cutoff values is the most sensible approach in order to avoid overdiagnosis.
6. Briganti A, Chun FK, Suardi N, et al. Prostate volume and adverse prostate cancer features: fact not artefact. Eur J Cancer 2007; 43:2669-2677. A small prostatic volume is related to the presence of aggressive prostate cancer. Prostate cancer detection and treatment strategies should account for prostate volume. (Pubitemid 350151846)
7. Okotie OT, Roehl KA, Han M, et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007; 70:1117-1120. (Pubitemid 350297358)
8. Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the European Randomized study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 2008; 54:581-588.
9. Gosselaar C, Roobol MJ, van den Bergh RCN, et al. Digital rectal examination and the diagnosis of prostate cancer: a study based on 8 years and three screenings within the European Randomized study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 2008 [Epub ahead of print].
10. Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008; 53:901-908. Within a screening setting with repeat visits, it does not seem necessary to biopsy all men with a PSA below 3.0 ng/ml.
11. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008; 6:19. Multiple kallikrein forms measured in blood can help in reducing unnecessary biopsies in previously unscreened men with elevated PSA.
12. Jansen FH, Roobol MJ, Jenster G, et al. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 2008 [Epub ahead of print].
13. Ahyai SA, Graefen M, Steuber T, et al. Contemporary prostate cancer prevalence among T1c biopsy-reffered men with a prostate-specific antigen level < or = 4.0 ng per millilitre. Eur Urol 2008; 53:750-757. (Pubitemid 351273880)
14. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Urology 2008; 10:175-181.
15. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large representative, unscreened population. J Clin Oncol 2008; 26:835-841. PSA velocity does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis.
16. Wolters T, Roobol MJ, Bangma CH, Schröder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009; 55:385-393. PSA velocity as a biopsy indicator would miss a large number of clinically significant prostate cancer cases.
17. Schröder FH, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008; 54:274-290.
18. Roobol MJ, Schröder FH. Re: Is a screening interval of every 4 years for prostate cancer acceptable? J Natl Cancer Inst 2008; 100:222; author reply 223-224. A shorter screening interval does not reduce the number of (aggressive) interval cancers.